如今,关于新冠肺炎疫情的很多重大问题仍然悬而未决——而这些问题或许在人们追踪疫情的进程时起着关键的作用,其中之一就是抗体在免疫系统中的作用。
到目前为止,在人体免疫、疫苗开发等方面,已经有很多和抗体相关的信息。这些Y形蛋白质通过对病原体或其他有害物质产生免疫反应而形成。它们可以根据每个病毒——即“抗原”的不同位置进行适配,并附着在这些抗原上,防止人们感染。
与许多病毒一样,人体在感染新冠病毒的过程中也会产生抗体,并形成保护作用,防止二次感染。但是,这些抗体的效力如何,在某些人群中形成的免疫力是否比其他人更强——这些问题的答案尚不明确。这就使人们面临“是否有可能二次感染”的问题。
一个可能需要数年时间才能够解答的关键疑问是:新冠病毒抗体的作用可以持续多久。
首先,抗体对每个人的作用不一定是完全相同的。在某些人体内,抗体形成的保护作用可能会更强大、更持久。而在其他一些所谓“自身适应性免疫功能较弱”的人体内,抗体的作用就可能较弱,他们与病毒的斗争也因此更加艰难,并且再次感染的风险更高——人体的生物机制会以无法预测的作用方式应对新的对手。
此外,新冠病毒本身就是一种新的病原体,携带有各种各样的致病因素:从普通感冒、SARS到MERS,所有这些病毒中含有的致病因素,它多多少少都带有一些。由于这些致病毒株的种类如此繁多,因此迄今为止,市场上尚无任何防治普通感冒的疫苗,也没有防治SARS或MERS的产品,而与新冠病毒相关的更是空白。
之所以出现这种情况,有一部分原因是,与新冠疫情相比,SARS和MERS疫情引起的病症都相对较轻,且SARS的控制速度相对较快。在SARS爆发时,人们发现,感染者体内的抗体所起到的保护作用平均能够持续两年。
然而新冠病毒似乎并非如此——至少对某些新冠患者而言。根据《新英格兰医学杂志》(New England Journal of Medicine)的一项研究,在轻症状患者中,抗体产生的保护效力可能会在两个多月内就减少一半。
本周,伦敦帝国理工学院(Imperial College London)的科学家发布了另一项新的分析结果,该报告研究了英国人体内的抗体水平。结果发现,在被研究的感染者群体中,抗体的数量急剧下降:从6月下旬的6%下降到9月下旬的4.4%。
研究论文的主要作者之一海伦•沃德说:“这项大规模的研究表明,随着时间的流逝,在体内可以检测出抗体的人的比例正在下降。”
但是还有另外一个可能:抗体水平的下降并不一定意味着会再次感染新冠。她说:“我们尚不知道,抗体水平下降是否会使这些患者有再次感染的风险。但至关重要的是,每个人都必须继续遵循防疫措施,以减少对自己和对他人的风险。”
其他研究也表明,存在康复患者二次感染的病例。两周前发表于《柳叶刀》(Lancet)的一篇文章报告了一个来自内华达州沃索县的25岁男子的病例,该男子在4月首次感染、5月底二次感染。
“重型新冠病毒感染产生的保护性免疫水平到底怎么样,目前尚不清楚。因此,再次感染该病毒的可能性有多大,我们还知之甚少。”来自内华达大学和内华达州立公共卫生图书馆的作者写道。
迄今为止,正如美国疾控中心指出的那样,“已经有相关研究报告了新冠患者再次感染的确诊或疑似病例,但仍然很少见。”
专家强调,“存在新冠病毒抗体”并不意味着具有持久的免疫力,或是能够保护他人免受感染——这反驳了那些“群体免疫”政策的支持者,他们相信只要让足够多的人感染,就可以在广泛的人群中起到免疫作用。
归根结底,勤洗手,戴口罩,保持社交距离依然十分必要——无论有没有抗体,都要为自己和他人的健康负责。(财富中文网)
编译:陈聪聪
如今,关于新冠肺炎疫情的很多重大问题仍然悬而未决——而这些问题或许在人们追踪疫情的进程时起着关键的作用,其中之一就是抗体在免疫系统中的作用。
到目前为止,在人体免疫、疫苗开发等方面,已经有很多和抗体相关的信息。这些Y形蛋白质通过对病原体或其他有害物质产生免疫反应而形成。它们可以根据每个病毒——即“抗原”的不同位置进行适配,并附着在这些抗原上,防止人们感染。
与许多病毒一样,人体在感染新冠病毒的过程中也会产生抗体,并形成保护作用,防止二次感染。但是,这些抗体的效力如何,在某些人群中形成的免疫力是否比其他人更强——这些问题的答案尚不明确。这就使人们面临“是否有可能二次感染”的问题。
一个可能需要数年时间才能够解答的关键疑问是:新冠病毒抗体的作用可以持续多久。
首先,抗体对每个人的作用不一定是完全相同的。在某些人体内,抗体形成的保护作用可能会更强大、更持久。而在其他一些所谓“自身适应性免疫功能较弱”的人体内,抗体的作用就可能较弱,他们与病毒的斗争也因此更加艰难,并且再次感染的风险更高——人体的生物机制会以无法预测的作用方式应对新的对手。
此外,新冠病毒本身就是一种新的病原体,携带有各种各样的致病因素:从普通感冒、SARS到MERS,所有这些病毒中含有的致病因素,它多多少少都带有一些。由于这些致病毒株的种类如此繁多,因此迄今为止,市场上尚无任何防治普通感冒的疫苗,也没有防治SARS或MERS的产品,而与新冠病毒相关的更是空白。
之所以出现这种情况,有一部分原因是,与新冠疫情相比,SARS和MERS疫情引起的病症都相对较轻,且SARS的控制速度相对较快。在SARS爆发时,人们发现,感染者体内的抗体所起到的保护作用平均能够持续两年。
然而新冠病毒似乎并非如此——至少对某些新冠患者而言。根据《新英格兰医学杂志》(New England Journal of Medicine)的一项研究,在轻症状患者中,抗体产生的保护效力可能会在两个多月内就减少一半。
本周,伦敦帝国理工学院(Imperial College London)的科学家发布了另一项新的分析结果,该报告研究了英国人体内的抗体水平。结果发现,在被研究的感染者群体中,抗体的数量急剧下降:从6月下旬的6%下降到9月下旬的4.4%。
研究论文的主要作者之一海伦•沃德说:“这项大规模的研究表明,随着时间的流逝,在体内可以检测出抗体的人的比例正在下降。”
但是还有另外一个可能:抗体水平的下降并不一定意味着会再次感染新冠。她说:“我们尚不知道,抗体水平下降是否会使这些患者有再次感染的风险。但至关重要的是,每个人都必须继续遵循防疫措施,以减少对自己和对他人的风险。”
其他研究也表明,存在康复患者二次感染的病例。两周前发表于《柳叶刀》(Lancet)的一篇文章报告了一个来自内华达州沃索县的25岁男子的病例,该男子在4月首次感染、5月底二次感染。
“重型新冠病毒感染产生的保护性免疫水平到底怎么样,目前尚不清楚。因此,再次感染该病毒的可能性有多大,我们还知之甚少。”来自内华达大学和内华达州立公共卫生图书馆的作者写道。
迄今为止,正如美国疾控中心指出的那样,“已经有相关研究报告了新冠患者再次感染的确诊或疑似病例,但仍然很少见。”
专家强调,“存在新冠病毒抗体”并不意味着具有持久的免疫力,或是能够保护他人免受感染——这反驳了那些“群体免疫”政策的支持者,他们相信只要让足够多的人感染,就可以在广泛的人群中起到免疫作用。
归根结底,勤洗手,戴口罩,保持社交距离依然十分必要——无论有没有抗体,都要为自己和他人的健康负责。(财富中文网)
编译:陈聪聪
One of the biggest outstanding questions about the coronavirus, and one which could well determine the course of the pandemic, is the role that antibodies play in immunity.
By now you've probably heard plenty about antibodies in the context of immunity and developing a COVID vaccine. These Y-shaped proteins form because of an immune response to a pathogen or other hostile biological material. They may be personalized to sites on an individual virus called antigens, to which they attach and help prevent infection.
As with many viruses, antibodies form during the course of a COVID case and should offer protection against against a second coronavirus infection. But it's still unclear just how potent these antibodies are and whether or not they may provide stronger immunity for some people more than others. And that raises the question of whether or not you can contract COVID-19 twice.
One central mystery that may take years to answer is how long COVID antibodies last. First off, antibodies don't always behave the same everyone. Some may form powerful antibodies with staying power; others whose body's so-called adaptive immune system produces weaker ones may face a much more brutal fight with COVID and be at a higher risk for reinfection. Human biology can react in unpredictable ways to new adversaries.
Then there's the type of pathogen that the novel coronavirus is itself. Coronaviruses encompass a broad class of bugs which can include everything from some types of the common cold to SARS and MERS. There is to date no cure or vaccine for the common cold since there is such a variety of strains. There also aren't any commercially available ones for SARS or MERS—or any coronaviruses for that matter.
Part of the reason for that is both the SARS and MERS outbreaks cause milder disease than COVID-19, and the former were contained relatively quickly. Patients who contracted SARS during that outbreak were found that have protective antibodies for an average of two years.
That doesn't seem to be the case with the novel coronavirus—at least for certain COVID patients. In those who suffer from a mild case, antibody levels may be cut in half in just over two months, according to one study in the New England Journal of Medicine.
Another new analysis by Imperial College London scientists released this week examined antibody levels among the British population. The report found that antibody prevalence dropped sharply and quickly in the study population: from 6% in late June to 4.4% in late September.
“This very large study has shown that the proportion of people with detectable antibodies is falling over time," said Helen Ward, one of the lead study authors.
But there's another twist: Those falling antibody levels don't necessarily mean you'll be reinfected with COVID. "We don’t yet know whether this will leave these people at risk of reinfection with the virus that causes COVID-19, but it is essential that everyone continues to follow guidance to reduce the risk to themselves and others," she said.
Other studies have shown there is a non-zero number of people who have been reinfected after recovering from COVID. A Lancet report published two weeks ago examined the case of a 25-year-old man from Washoe County in Nevada who contracted COVID-19 once in April and again at the end of May.
"The degree of protective immunity conferred by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently unknown. As such, the possibility of reinfection with SARS-CoV-2 is not well understood," wrote the authors from the University of Nevada and Nevada State Public Health Library.
To date, as the Centers for Disease Control (CDC) puts it, "confirmed and suspected cases of reinfection of the virus that causes COVID-19 have been reported, but remain rare."
Experts stress that the mere presence of coronavirus antibodies is no reason to assume you'll have long-lasting immunity or protect others from infection. The latter point throws a big wrench into proponents of a "herd immunity" approach wherein you simply let enough people get infected and become immune.
At the end of the day, it is still be important to wash your hands, wear a mask, socially distance, and be generally responsible—antibodies or otherwise.